CD274 and ovarian carcinoma: Currently, research has revealed that immunotherapies involving PD-1 or PD-L1 blockade have superior efficacy in the treatment of various cancers, including non-small cell lung cancer (28), melanoma (29), breast cancer (30), ovarian cancer (31), and classical Hodgkin lymphoma (32).